DocGo vs Strata Critical Medical
DCGO and SRTA side by side, both in transportation services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DCGO and SRTA compare
Strata Critical Medical is the larger company, worth 24 times as much as DocGo ($487M against $20.5M).
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus −19.2% for DocGo).
Strata Critical Medical keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −61.0% at DocGo.
Strata Critical Medical scores higher on the StockData Score (17 against 6 for DocGo), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DCGO | SRTA |
|---|---|---|
| Size and price | ||
| Market cap | $20.5M | $487M |
| Share price | $0.208 | $5.51 |
| Change, 1 year | −80.9% | 8.0% |
| Change, 5 years | −97.8% | −43.0% |
| Beta (5Y) | 1.24 | 1.63 |
| Employees | 3,600 | 601 |
| StockData Score | ||
| Total score | 6 | 17 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 0 | 4 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 10.8× |
| P/S | 0.1× (better) | 1.9× |
| P/B | 0.2× (better) | 1.7× |
| FCF yield | −148% | −9.9% (better) |
| Fair value | $2.15 | $8.72 |
| Margin of safety | 90.3% (better) | 36.8% |
| Growth | ||
| Revenue growth (TTM) | −19.2% | 66.8% (better) |
| Revenue growth, 5Y average | 27.9% | 44.6% (better) |
| Profitability | ||
| Gross margin | – | 20.6% |
| Operating margin | −53.3% | −8.0% (better) |
| Net margin | −61.0% | 15.7% (better) |
| FCF margin | −10.2% (better) | −18.9% |
| Return on equity | −96.5% | 16.0% (better) |
| Return on invested capital | −88.3% | −8.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 1.38 | 2.64 (better) |
| Altman Z-score | −2.82 | 5.67 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 38.5% | 63.0% |
| Held by insiders | 9.8% | 21.0% |
| Insider net buying, 12 months | −$15.3K (better) | −$724K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.4% | 6.5% |
Go deeper
- DCGO stock overview
- DCGO income statement
- DCGO valuation and score
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.